Time filter

Source Type

Whitehouse Station, NJ, United States

The pseudo-neutralization assay (PsV) described in the current report allows for the creation of HPV18 pseudovirions in order to evaluate whether the antibody responses elicited following vaccination with Gardasil(®) are sufficient to neutralize the activity of these pseudovirions in vitro. The PsV assay evaluates a broader antibody response than the HPV competitive Lumniex Immunoassay (cLIA), which monitors the presence of a single neutralizing epitope. We employed two different approaches to the HPV18-PsV assay: one using standard dilutions of heat inactivated serum from vaccinated subjects, as is typically reported in the literature, and the other using heat inactivated serum from which IgG antibodies were purified and quantitated as an attempt to reduce assay background and achieve a level of quantitation greater than that afforded through simple dilution. Here, we show that after 48 mo, Gardasil(®) vaccinated subjects from three groups defined by HPV 18 cLIA titer have detectable HPV18 neutralizing antibodies as measured by either approach in the HPV18-PsV assay. These data support the observed sustained HPV18 protection against persistent infection and disease with the absence of breakthrough cases in Gardasil(®) vaccinees and suggests that neutralizing antibodies are present although they may no longer be detectable by cLIA. Source

There is a long history of productive collaboration between biomedical scientists in academia and in the pharmaceutical industry. The primary beneficiary of this collaboration has been the public. Since the middle of the last century, marked advances in the treatment and prevention of disease have been driven by the translational research interactions across these two domains. But now, at a time when collaboration between academia and industry should be accelerating based on past success, new technology, and ever-increasing need, numerous obstacles to effective collaboration have appeared. In this analysis, based on experience in both academia and industry, the author provides perspective on current obstacles to academic-industrial collaboration, followed by recommendations on how effective collaboration can be renewed and enhanced. Copyright © 2013 by the American Thoracic Society. Source

The present invention relates to a process for the selective enzymatic hydrolysis of C-terminal esters of peptide substrates in the synthesis of peptides, comprising hydrolysing C-terminal tert-butyl esters using the protease subtilisin. This process is useful in the production of protected or unprotected peptides.

ARIAD Pharmaceuticals Inc. and Merck | Date: 2014-04-30

The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an v62 3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.

Merck | Date: 2012-07-03

The invention relates generally to methods for purifying a Fc-fusion protein produced in a eukaryotic expression system. More specifically, the invention provides a robust and scalable downstream purification process suitable for use in manufacturing TNFR:Fc for human administration which comprises an optimized Protein A affinity chromatography step and two ion exchange chromatography steps both of which are operated in the bind-and-elute mode.

Discover hidden collaborations